You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
东阳光药(01558.HK)吐逾7%曾失43元 成交倍增
阿思达克 11-18 11:21

斥逾20亿人民币收购系内公司两种治疗2型糖尿病产品的东阳光药(01558.HK)反弹受制10天线後,今天股价失守20天线(26.22元),沽盘持续涌现,最多挫9.1%低见42.6元喘定,现造43.5元,急吐7.2%,成交倍增至337万股,涉资1.48亿元。

东阳光药上周中公布关连交易,以现金总代价代价20.57亿人民币向系内的广东东阳光药业收购两种治疗2型糖尿病产品,包括焦谷氨酸荣格列净及利拉鲁(月太),彼即将开展三期临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account